CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDI CALIDI BIOTHERAPEUTICS INC

Market Closed 03-27 16:00:00 EDT

0.2707

-0.0105

-3.75%

盘后0.2680

-0.0027-1.00%

19:38 EDT

High0.2754	Low0.2620	Vol237.33K
Open0.2717	D1 Closing0.2813	Amplitude4.76%
Mkt Cap1.99M	Tradable Cap1.72M	Total Shares7.37M
T/O63.79K	T/O Rate3.73%	Tradable Shares6.36M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLDI","market":"US","secType":"STK","nameCN":"CALIDI BIOTHERAPEUTICS INC","latestPrice":0.2707,"timestamp":1774641600000,"preClose":0.28125,"halted":0,"volume":237333,"hourTrading":{"tag":"盘后","latestPrice":0.268,"preClose":0.2707,"latestTime":"19:38 EDT","volume":763,"amount":207.6597,"timestamp":1774654733644,"change":-0.0027,"changeRate":-0.009974,"amplitude":0.017732},"delay":0,"changeRate":-0.03751111111111113,"floatShares":6364800,"shares":7367000,"eps":-9.021739,"marketStatus":"Market Closed","change":-0.01055,"latestTime":"03-27 16:00:00 EDT","open":0.2717,"high":0.2754,"low":0.262,"amount":63792.357337199996,"amplitude":0.047644,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.021739,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":0.28125,"preHourTrading":{"tag":"盘前","latestPrice":0.2812,"preClose":0.2812,"latestTime":"09:28 EDT","volume":2573,"amount":724.10284561,"timestamp":1774618101783,"change":0,"changeRate":0,"amplitude":0.007468},"postHourTrading":{"tag":"盘后","latestPrice":0.268,"preClose":0.2707,"latestTime":"19:38 EDT","volume":763,"amount":207.6597,"timestamp":1774654733644,"change":-0.0027,"changeRate":-0.009974,"amplitude":0.017732},"volumeRatio":0.6027646871987881},"requestUrl":"/m/hq/s/CLDI","defaultTab":"news","newsList":[{"id":"2622808985","title":"Calidi Biotherapeutics FY2025 loss per share narrows 83.33% to $5.95; revenue falls 41.67% to $50,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808985","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622808985?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:25","pubTimestamp":1774643151,"startTime":"0","endTime":"0","summary":"Calidi published a press release reporting fourth-quarter and full-year 2025 financial results and recent operational updates.Net loss attributable to common stockholders was USD 4.1 million for Q4, or USD 0.57 per share.R&D expense rose 33.33% to USD 2.4 million in Q4, while G&A expense fell 4.55% to USD 2.1 million.Net loss attributable to common stockholders was USD 25.6 million for FY 2025, or USD 5.95 per share.Cash was USD 5.6 million at Dec. 31, 2025, and the company said it expects to file an IND for CLD-401 by end of 2026 after FDA Type D interactions and partnerships with Avance Clinical and Matica Bio.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8W50W3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4112","LU2095319765.USD","CLDI","SG9999014005.SGD","IE00BN0W2T93.GBP","BK4588","BK4585","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","NDAQ","SG9999014039.USD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014021.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2622089578","title":"Calidi Biotherapeutics Inc: Q4 Net Loss per Share $0.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2622089578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622089578?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:25","pubTimestamp":1774643133,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nTUA4XNBYG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2622808987","title":"Press Release: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622808987?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:25","pubTimestamp":1774643100,"startTime":"0","endTime":"0","summary":"-- Announced partnership with Australian CRO to accelerate initiation of. -- The Company has received feedback from the FDA through Type D. interactions, and the Company believes its manufacturing and analytical. approaches for CLD-401 are in alignment with FDA guidance; Calidi expects. -- Partnered with Matica Bio around the GMP manufacturing of CLD-401. -- Presented new data on in situ T-cell engagers  at 2026 AACR-IO. SAN DIEGO, March 27, 2026  -- Calidi Biotherapeutics Inc.  , a biotechnology company pioneering the development of targeted genetic medicines, today reported its fourth quarter and full-year 2025 operating and financial results and reviewed recent business highlights.\"We are extremely excited about the continued progress at Calidi,\" said Eric Poma, PhD, CEO of Calidi Biotherapeutics. \"We continue to advance CLD-401, the first lead from our RedTail platform, towards the clinic and have built a world-class scientific advisory board to aid those efforts. We have also expa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2621106425","title":"BRIEF-Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2621106425","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621106425?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:18","pubTimestamp":1774354706,"startTime":"0","endTime":"0","summary":"BRIEF-Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory ApprovalMarch 24 (Reuters) - Calidi Biotherapeutics Inc CLDI.A:CALIDI BIOTHERAPEUTICS ANNOUN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C09V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2621064472","title":"Calidi Biotherapeutics Announces Partnership With Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of Cld-401 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064472?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:16","pubTimestamp":1774354598,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C09V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2621064600","title":"Calidi Biotherapeutics partners with Avance Clinical on CLD-401 trial launch in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064600","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064600?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:04","pubTimestamp":1774353885,"startTime":"0","endTime":"0","summary":"Calidi partnered with Avance Clinical to support Australian regulatory approval and accelerate initiation of first-in-human clinical trials for CLD-401 in Australia.The collaboration is intended to facilitate clinical trial initiation in Australia while Calidi pursues an FDA IND filing in 2026.CLD-401 is a genetically modified vaccinia virus designed to replicate only in tumor cells and express an IL-15 superagonist in the tumor microenvironment.The planned phase I trial will evaluate safety and pharmacodynamics in patients with solid tumors.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL7fnRVd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4112","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","BK4585","BK4588","CLDI","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014021.USD"],"gpt_icon":0},{"id":"2618134673","title":"Calidi Biotherapeutics presents CLD-401 manufacturing process at BioProcessing Summit in Barcelona","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134673","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134673?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:03","pubTimestamp":1773316990,"startTime":"0","endTime":"0","summary":"Calidi presented its manufacturing process for CLD-401 at the 9th Annual Bioprocessing Summit in Barcelona. The company said it has received FDA feedback through a Type D meeting request process related to its manufacturing and analytical approaches for CLD-401. Antonio Santidrian and Eric Poma spoke about the manufacturing strategy and regulatory interactions during the event.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL2FDp2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","NDAQ","SG9999014005.SGD","LU2095319765.USD","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","CLDI","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","SG9999014013.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2618411976","title":"Calidi Biotherapeutics announces proposed underwritten public offering of stock and warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2618411976","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618411976?lang=en_us&edition=fundamental","pubTime":"2026-03-12 05:12","pubTimestamp":1773263543,"startTime":"0","endTime":"0","summary":"Calidi said it plans an underwritten public offering of units consisting of common stock and, for certain investors, pre-funded warrants in lieu of common stock. Each unit will include accompanying common warrants to purchase common stock, and the securities will separate immediately upon issuance. The pre-funded warrants will be priced at the public offering price minus USD 0.001 per share, with an exercise price of USD 0.001 per share. Calidi expects to grant the underwriters a 45-day option to buy up to an additional 15% of the shares and/or common warrants offered. Ladenburg Thalmann is acting as sole book-running manager, and Calidi said it intends to use net proceeds for working capital and general corporate purposes.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL8zKJLP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTSAP","BK4127","CLDI","BK4139"],"gpt_icon":0},{"id":"2618060623","title":"Press Release: Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2618060623","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618060623?lang=en_us&edition=fundamental","pubTime":"2026-03-10 08:50","pubTimestamp":1773103800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 09, 2026  -- Calidi Biotherapeutics, Inc.  , a biotechnology company pioneering the development of targeted genetic medicines, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters' over-allotment option for gross proceeds of approximately $6.0 million, prior to deducting underwriting commissions and offering expenses.In connection with the offering, the Company sold 12,094,631 shares of common stock  Series J warrants to purchase 12,094,631 shares of common stock, Series K warrants to purchase 12,094,631 shares of common stock, and Series L warrants to purchase 12,094,631 shares of common stock, including the full exercise of the underwriter's option to purchase 1,575,000 shares of common stock and accompanying warrants..Ladenburg Thalmann & Co. Inc. acted as sole book-running manager for the offering.This press release does not constitute an offer to sell or the solicitation of an offer to bu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2617263825","title":"BRIEF-Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2617263825","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617263825?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:34","pubTimestamp":1772804052,"startTime":"0","endTime":"0","summary":"BRIEF-Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public OfferingMarch 6 (Reuters) - Calidi Biotherapeutics Inc CLDI.A:CALIDI BIOTHERAPEUTICS ANNOUNCES PRICING OF $5.2 MILLIO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nTUA92TXCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2617883716","title":"Calidi Biotherapeutics (CLDI) Stock Plunges 35% After Hours — Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2617883716","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617883716?lang=en_us&edition=fundamental","pubTime":"2026-03-06 15:15","pubTimestamp":1772781300,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics shares plunged after hours following a public offering announcement, trading near their 52-week low.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/06/Stock-Market-Analysis-Shows-Trading-Patt.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/06/Stock-Market-Analysis-Shows-Trading-Patt.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/03/51089549/calidi-biotherapeutics-cldi-stock-plunges-35-after-hours-heres-why","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/03/51089549/calidi-biotherapeutics-cldi-stock-plunges-35-after-hours-heres-why","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4150","RSI","CLDI","BK4139"],"gpt_icon":0},{"id":"2617657213","title":"Calidi announces offering of units, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2617657213","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617657213?lang=en_us&edition=fundamental","pubTime":"2026-03-06 07:00","pubTimestamp":1772751646,"startTime":"0","endTime":"0","summary":"Calidi (CLDI) Biotherapeutics announced that it intends to offer and sell, subject to market and other conditions, units consisting of shares of it...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/calidi-announces-offering-of-units-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/calidi-announces-offering-of-units-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2617572540","title":"Calidi Biotherapeutics Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2617572540","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617572540?lang=en_us&edition=fundamental","pubTime":"2026-03-06 06:57","pubTimestamp":1772751449,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA4YJHRP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2612262397","title":"Calidi Biotherapeutics Inc. Publishes RedTail Systemic Platform Poster on Tumor-Specific BiTE Delivery and Immune Activation","url":"https://stock-news.laohu8.com/highlight/detail?id=2612262397","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612262397?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:05","pubTimestamp":1771592735,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. published a medical research poster on the RedTail systemic gene therapy platform focused on tumor-specific delivery and localized expression of immune-activating payloads, including an IL-15 superagonist and bispecific T-cell engagers . The document describes the use of an engineered extracellular enveloped vaccinia virus designed for systemic administration, selective tumor replication, oncolysis, and complement resistance via CD55, and includes preclinical findings on tumor-localized payload levels, immune cell activation, and responses in a breast tumor model. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL5LBbhj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2612079264","title":"Calidi Biotherapeutics Advances CLD-401 Toward IND-Enabling Studies Using RedTail Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2612079264","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612079264?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:00","pubTimestamp":1771592429,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced that it presented preclinical data at the 2026 AACR Immuno-Oncology  conference on its RedTail platform approach to bispecific T-cell engagers  for solid tumors. The company reported that RedTail viruses were able to express a functional tumor-targeting BiTE together with an IL-15 superagonist in the tumor microenvironment, aiming to support T-cell activation and tumor-localized targeting. Calidi also said it is conducting IND-enabling studies for CLD-401, its lead RedTail-derived candidate, and expects to submit an IND application by the end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL9vN6hK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","NDAQ","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","BK4112","SG9999014013.SGD","LU0314104364.USD","BK4139","LU2210149790.SGD","BK4588","BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","CLDI"],"gpt_icon":0},{"id":"2610892950","title":"Calidi Biotherapeutics Presents RedTail Platform Data at AACR-IO Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2610892950","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610892950?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:02","pubTimestamp":1770901325,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced that it will present data on its novel RedTail platform for Bispecific T-Cell Engagers  in solid tumors at the AACR Immuno-Oncology  conference in Los Angeles, California, from February 18-21, 2026. The company will showcase how its systemically delivered virotherapy platform targets tumors and remodels the tumor microenvironment to enable T-cell engagement and localized expression of therapeutic genetic payloads. Calidi is also advancing its lead candidate, CLD-401, toward an IND submission by the end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 12, 2026, and is sol","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDLQYRdj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","IE00B3QW5Z07.USD","CLDI","NDAQ","SG9999014021.USD","IE00BKPKM429.USD","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","LU2210150020.SGD","LU2095319765.USD","BK4139","SG9999014039.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2609351794","title":"Calidi Biotherapeutics unveils RedTail platform for precision genetic medicine delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2609351794","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609351794?lang=en_us&edition=fundamental","pubTime":"2026-02-07 07:38","pubTimestamp":1770421117,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. has outlined updates on its RedTail platform, which is designed for the precise delivery of genetic medicines to disease sites, including cancer. The company highlighted new leadership appointments and a revamped Scientific Advisory Board to support the advancement of the RedTail platform. Calidi reported progress in its pipeline, with initial data on RedTail and its CLD-401 program presented in 2025. The company stated it has reduced its debt significantly and plans to allocate around 70% of its forecasted 2026 spending to research and development. The RedTail platform leverages a vaccinia virus scaffold with a high capacity for genetic payloads and aims to improve systemic delivery of oncolytic viruses by reducing immune system recognition. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely inf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDLqwDG7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"gpt_icon":0},{"id":"2607085300","title":"Calidi Biotherapeutics to File IND for CLD-401 in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2607085300","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607085300?lang=en_us&edition=fundamental","pubTime":"2026-01-29 19:01","pubTimestamp":1769684501,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced a corporate update outlining key milestones achieved in 2025 and plans for 2026. The company reported successful execution of its 2025 priorities, including demonstrating in clinically relevant immunocompetent murine models and ex vivo human immune assays that its RedTail platform can prevent immune clearance after systemic administration and selectively replicate in tumor cells. Calidi plans to file an Investigational New Drug  application in the fourth quarter of 2026 for its first RedTail lead candidate, CLD-401, which is designed to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease. Additionally, Calidi expects to present proof-of-concept data in 2026 demonstrating the versatility of the RedTail platform, including the simultaneous delivery of tumor-localized Bi-specific T cell engagers  alongside T-cell amplifiers. The company also aims to expand the platform’s applicability to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL2PVHwL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"gpt_icon":0},{"id":"2606224719","title":"Calidi Biotherapeutics Slashes Debt by $3.1 Million in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2606224719","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606224719?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:00","pubTimestamp":1769605220,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics Inc. announced that it reduced its term debt and notes payable, including accrued interest, by $3.1 million in 2025. The company’s debt decreased from $3.8 million at the end of 2024 to $0.7 million at the end of 2025, according to unaudited figures.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDLTytHv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014005.SGD","LU2210150020.SGD","SG9999014013.SGD","LU0314104364.USD","BK4585","BK4588","CLDI","IE00B64PRP62.GBP","SG9999014039.USD","BK4139","IE00BKPKM429.USD","BK4112","SG9999014021.USD","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2606719200","title":"Calidi Biotherapeutics Inc - to File Ind for Cld-401 in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606719200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606719200?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:00","pubTimestamp":1769605206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nTUA5BSZLD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDI","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.calidibio.com","stockEarnings":[{"period":"1week","weight":-0.0435},{"period":"1month","weight":-0.6699},{"period":"3month","weight":-0.7817},{"period":"6month","weight":-0.8276},{"period":"1year","weight":-0.9676},{"period":"ytd","weight":-0.7686}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.185839},{"month":2,"riseRate":0.6,"avgChangeRate":-0.062337},{"month":3,"riseRate":0.4,"avgChangeRate":-0.212827},{"month":4,"riseRate":0.25,"avgChangeRate":-0.200168},{"month":5,"riseRate":0.25,"avgChangeRate":-0.071752},{"month":6,"riseRate":0.75,"avgChangeRate":-0.069766},{"month":7,"riseRate":0.75,"avgChangeRate":0.345315},{"month":8,"riseRate":0.25,"avgChangeRate":-0.291823},{"month":9,"riseRate":0,"avgChangeRate":-0.182897},{"month":10,"riseRate":0.75,"avgChangeRate":-0.07151},{"month":11,"riseRate":0.5,"avgChangeRate":0.188661},{"month":12,"riseRate":0.2,"avgChangeRate":-0.191351}],"exchange":"AMEX","name":"CALIDI BIOTHERAPEUTICS INC","nameEN":"CALIDI BIOTHERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CALIDI BIOTHERAPEUTICS INC,CLDI,CALIDI BIOTHERAPEUTICS INC股票,CALIDI BIOTHERAPEUTICS INC股票老虎,CALIDI BIOTHERAPEUTICS INC股票老虎国际,CALIDI BIOTHERAPEUTICS INC行情,CALIDI BIOTHERAPEUTICS INC股票行情,CALIDI BIOTHERAPEUTICS INC股价,CALIDI BIOTHERAPEUTICS INC股市,CALIDI BIOTHERAPEUTICS INC股票价格,CALIDI BIOTHERAPEUTICS INC股票交易,CALIDI BIOTHERAPEUTICS INC股票购买,CALIDI BIOTHERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CALIDI BIOTHERAPEUTICS INC(CLDI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CALIDI BIOTHERAPEUTICS INC(CLDI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction